Maxim Group downgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Buy to Hold.Analyst Jason McCarthy commented:Keryx and Akebia Therapeutics announced a definitive ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE